Literature DB >> 15278047

Healing rate of EMR-induced ulcer in relation to the duration of treatment with omeprazole.

Sun-Young Lee1, Jae J Kim, Jun Haeng Lee, Young-Ho Kim, Poong-Lyul Rhee, Seung Woon Paik, Jong Chul Rhee.   

Abstract

BACKGROUND: Although EMR-induced ulcers heal faster and recur less often than noniatrogenic gastric ulcers, there is no consensus regarding the duration of therapy for these ulcers. This study prospectively evaluated healing of EMR-induced ulcers according to the duration of omeprazole therapy.
METHODS: A total of 69 patients were randomly assigned, after EMR, to treatment with omeprazole (20 mg per day) for 7 days (1-week group) or with omeprazole (20 mg per day) for 28 days (4-week group). Four weeks after EMR, ulcer size and stage were compared with those of the initial EMR-induced ulcer. Each patient kept a daily diary of drugs consumed and ulcer-related symptoms during the 4-week period after EMR.
RESULTS: Thirty-four patients were randomized to the 4-week group, and 26 were randomized to the 1-week group. No significant differences were observed between the two groups at 4 weeks after EMR in terms of ulcer reduction ratio (p=0.29) or stage (p=0.11). In addition, no difference was observed between the two groups with respect to ulcer-related symptoms or use of additional gastric-coating medication (p=0.48).
CONCLUSIONS: For EMR-induced ulcer, treatment with omeprazole for 1 week is equivalent to treatment for 4 weeks. Short-term therapy with omeprazole can be considered for EMR-induced ulcer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15278047     DOI: 10.1016/s0016-5107(04)01683-9

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  28 in total

1.  Optimal duration of proton pump inhibitor for healing artificial ulcers after endoscopic submucosal dissection for early gastric cancer.

Authors:  Takuji Gotoda
Journal:  Dig Dis Sci       Date:  2011-12-25       Impact factor: 3.199

2.  Management of bleeding and artificial gastric ulcers associated with endoscopic submucosal dissection.

Authors:  Yosuke Muraki; Shotaro Enomoto; Mikitaka Iguchi; Mitsuhiro Fujishiro; Naohisa Yahagi; Masao Ichinose
Journal:  World J Gastrointest Endosc       Date:  2012-01-16

3.  Endoscopic mucosal resection and endoscopic submucosal dissection as treatments for early gastrointestinal cancers in Western countries.

Authors:  Sergio Coda; Sun-Young Lee; Takuji Gotoda
Journal:  Gut Liver       Date:  2007-06-30       Impact factor: 4.519

4.  Comparison of the efficacy of 4- and 8-week lansoprazole treatment for ESD-induced gastric ulcers: a randomized, prospective, controlled study.

Authors:  Ji Hoon Park; Eun Kyung Baek; Chang Hwan Choi; Kyung Hun Lee; Beom Jin Kim; Jeong Wook Kim; Jae Gyu Kim; Sae Kyung Chang
Journal:  Surg Endosc       Date:  2013-08-31       Impact factor: 4.584

5.  Optimal duration of proton pump inhibitor in the treatment of endoscopic submucosal dissection-induced ulcers: a retrospective analysis and prospective validation study.

Authors:  Suck-Ho Lee; Chang Kyun Lee; Il-Kwun Chung; Yun Suk Shim; Tae Hoon Lee; Sae Hwan Lee; Hong-Soo Kim; Sang-Heum Park; Sun-Joo Kim
Journal:  Dig Dis Sci       Date:  2011-10-15       Impact factor: 3.199

Review 6.  Endoscopic resection of early gastric cancer.

Authors:  Takuji Gotoda
Journal:  Gastric Cancer       Date:  2007-02-23       Impact factor: 7.370

Review 7.  Endoscopic mucosal resection of early gastric cancer: Experiences in Korea.

Authors:  Jun-Haeng Lee; Jae J Kim
Journal:  World J Gastroenterol       Date:  2007-07-21       Impact factor: 5.742

8.  A matched case-control study of a novel Acid-pump antagonist and proton-pump inhibitor for the treatment of iatrogenic ulcers caused by endoscopic submucosal dissection.

Authors:  Yong Gil Kim; Byung-Ik Jang; Tae Nyeun Kim
Journal:  Gut Liver       Date:  2010-03-25       Impact factor: 4.519

9.  Clinical trial: rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection--a randomized controlled study.

Authors:  Tomohiro Kato; Hiroshi Araki; Fumito Onogi; Takashi Ibuka; Akihiko Sugiyama; Eiichi Tomita; Masahito Nagaki; Hisataka Moriwaki
Journal:  J Gastroenterol       Date:  2009-12-03       Impact factor: 7.527

10.  Rebamipide may be comparable to H2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: a prospective randomized pilot study.

Authors:  Yu Jin Kim; Jae Hee Cheon; Sang Kil Lee; Jie Hyun Kim; Yong Chan Lee
Journal:  J Korean Med Sci       Date:  2010-03-19       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.